{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:36:25Z","timestamp":1785576985018,"version":"3.56.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["781907"],"award-info":[{"award-number":["781907"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jchromb.2023.123801","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T13:12:48Z","timestamp":1687957968000},"page":"123801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Standardization and validation of a novel UPLC-MS\/MS method to quantify first line anti-tuberculosis drugs in plasma and dried blood spots"],"prefix":"10.1016","volume":"1228","author":[{"given":"Ivette Guadalupe","family":"Herrera-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Socorro","family":"Rodr\u00edguez-B\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Ortiz-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Velarde-Salcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Arriaga-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian Jazm\u00edn","family":"Rodr\u00edguez-Pinal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Romano-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa del Carmen","family":"Mil\u00e1n-Segovia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna Edith","family":"Medell\u00edn-Garibay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2023.123801_b0005","unstructured":"World Health Organization, National Tuberculosis Control Programme For Ending TB, 2020-2024. Available in: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/333646\/National-Plan-TB2020-2024-eng.pdf."},{"key":"10.1016\/j.jchromb.2023.123801_b0010","unstructured":"Centers for Disease Control and Prevention, TB Disease, (2020). Available in:https:\/\/www.cdc.gov\/tb\/publications\/guidelines\/default.htm."},{"key":"10.1016\/j.jchromb.2023.123801_b0015","first-page":"1","article-title":"The impact of first-line anti-tubercular drugs\u2019 pharmacokinetics on treatment outcome: A systematic review","volume":"13","author":"Sileshi","year":"2021","journal-title":"Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2023.123801_b0020","doi-asserted-by":"crossref","unstructured":"S.E. Medellin-Garibay, A.P. Huerta-Garc\u00eda, A.S. Rodr\u00edguez-B\u00e1ez, M. Maga\u00f1a-Aquino, A. Ortiz-\u00c1lvarez, D.P. Portales-P\u00e9rez, R. del C. Mil\u00e1n-Segovia, S. Romano-Moreno, A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis, Tuberculosis. 124 (2020). http:\/\/doi.org\/10.1016\/j.tube.2020.101982.","DOI":"10.1016\/j.tube.2020.101982"},{"key":"10.1016\/j.jchromb.2023.123801_b0025","doi-asserted-by":"crossref","unstructured":"A.P. Huerta-Garc\u00eda, S.E. Medell\u00edn-Garibay, R.A. Salazar-Gonz\u00e1lez, A. Ortiz-\u00c1lvarez, M. Maga\u00f1a-Aquino, C.J. Rodr\u00edguez-Pinal, D.P. Portales-P\u00e9rez, S. Romano-Moreno, R. Del, C. Mil\u00e1n-Segovia, Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis, (2019) doi:10.1097\/FTD.0000000000000631.","DOI":"10.1097\/FTD.0000000000000631"},{"key":"10.1016\/j.jchromb.2023.123801_b0030","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3343\/alm.2016.36.5.489","article-title":"Multiplex Assay of Second-Line Anti-Tuberculosis Drugs in Dried Blood Spots Using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry","volume":"36","author":"Lee","year":"2016","journal-title":"Ann Lab Med."},{"key":"10.1016\/j.jchromb.2023.123801_b0035","doi-asserted-by":"crossref","unstructured":"K. Lee, S.H. Jun, M.S. Choi, S.H. Song, J.S. Park, J.H. Lee, K.U. Park, J. Song, Application of the isoniazid assay in dried blood spots using the ultra-performance liquid chromatography-tandem mass spectrometry, Clin. Biochem. 50 (2017) 882\u2013885. http:\/\/doi.org\/10.1016\/j.clinbiochem.2017.04.010.","DOI":"10.1016\/j.clinbiochem.2017.04.010"},{"key":"10.1016\/j.jchromb.2023.123801_b0040","doi-asserted-by":"crossref","unstructured":"Y. Harahap, B. Maggadani, Asian Journal of Scientific Research Analysis of Rifampicin in Dried Blood Spots Using High Performance Liquid Chromatography DETERMINATION OF SIBUTRAMINE ADULTERATED IN HERBAL SLIMMING PRODUCTS USING TLC DENSITOMETRIC METHOD View project Rifampicin View project, (2018). 10.3923\/ajsr.2018.","DOI":"10.3923\/ajsr.2018.232.239"},{"key":"10.1016\/j.jchromb.2023.123801_b0045","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/10408363.2017.1297358","article-title":"Clinical perspectives of dried blood spot protein quantification using mass spectrometry methods","volume":"54","author":"Lehmann","year":"2017","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.jchromb.2023.123801_b0050","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijantimicag.2018.04.020","article-title":"Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children","volume":"52","author":"Martial","year":"2018","journal-title":"Int. J. Antimicrob. Agents."},{"key":"10.1016\/j.jchromb.2023.123801_b0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.talanta.2013.12.043","article-title":"Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS\/MS","volume":"121","author":"Vu","year":"2014","journal-title":"Talanta."},{"key":"10.1016\/j.jchromb.2023.123801_b0060","unstructured":"U.S. Deparment of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Bioanalytical Method Validation Guidance for Industry Biopharmaceutics Bioanalytical Method Validation Guidance for Industry Biopharmaceutics Contains Nonbinding Recommendations, 2018. Available in: https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf."},{"key":"10.1016\/j.jchromb.2023.123801_b0065","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00216-019-02334-8","article-title":"Bioanalytical method validation: How much should we do and how should we document?","volume":"412","author":"Hopfgartner","year":"2020","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jchromb.2023.123801_b0070","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.4155\/bio-2022-0167","article-title":"Bioanalytical method validation and sample analysis for nirmatrelvir in dried blood collected using the Tasso-M20 device","volume":"14","author":"Wan","year":"2022","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2023.123801_b0075","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jchromb.2023.123801_b0080","doi-asserted-by":"crossref","unstructured":"Y. Harahap, F. Alkindy, G. Ashiila, R. R, Analysis of Rifampicin in Dried Blood Spot of Tuberculosis Patients for Therapeutic Drug Monitoring using High Performance Liquid Chromatography, J. Young Pharmacists. 10 (2018) 48\u201351. http:\/\/doi.org\/10.5530\/jyp.2018.10.12.","DOI":"10.5530\/jyp.2018.10.12"},{"key":"10.1016\/j.jchromb.2023.123801_b0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.talanta.2013.12.043","article-title":"Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC\u2013MS\/MS","volume":"121","author":"Vu","year":"2014","journal-title":"Talanta"},{"key":"10.1016\/j.jchromb.2023.123801_b0090","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s40262-014-0177-7","article-title":"Therapeutic drug monitoring by dried blood spot: progress to date and future directions","volume":"53","author":"Li","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2023.123801_b0095","doi-asserted-by":"crossref","unstructured":"H. Kawanami, Y. Himeda, G. Laurenczy, Formic Acid as a Hydrogen Carrier for Fuel Cells Toward a Sustainable Energy System, in: 2017: pp. 395\u2013427. 10.1016\/bs.adioch.2017.04.002.","DOI":"10.1016\/bs.adioch.2017.04.002"},{"key":"10.1016\/j.jchromb.2023.123801_b0100","doi-asserted-by":"crossref","unstructured":"X. Zheng, E.M. Jongedijk, Y. Hu, J. Kuhlin, R. Zheng, K. Niward, J. Paues, B. Xu, L. Davies Forsman, T. Sch\u00f6n, J. Bruchfeld, J.-W.C. Alffenaar, Development and validation of a simple LC-MS\/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma, J. Chromatogr. B. 1158 (2020) 122397. http:\/\/doi.org\/10.1016\/j.jchromb.2020.122397.","DOI":"10.1016\/j.jchromb.2020.122397"},{"key":"10.1016\/j.jchromb.2023.123801_b0105","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/jac\/dku457","article-title":"Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents","volume":"70","author":"Lakshminarayana","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.jchromb.2023.123801_b0110","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1021\/acs.chemrev.8b00246","article-title":"Column Characterization and Selection Systems in Reversed-Phase High-Performance Liquid Chromatography","volume":"119","author":"Zuvela","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jchromb.2023.123801_b0115","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.2174\/138161211797470174","article-title":"Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization","volume":"17","author":"Vu","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jchromb.2023.123801_b0120","doi-asserted-by":"crossref","unstructured":"L. Wu, Z. Ye, H. Liu, H. Guo, J. Lin, L. Zheng, N. Chu, X. Liu, Rapid and highly sensitive quantification of the anti-tuberculosis agents isoniazid, ethambutol, pyrazinamide, rifampicin and rifabutin in human plasma by UPLC-MS\/MS, J. Pharm. Biomed. Anal., 180 (2020) 113076. http:\/\/doi.org\/10.1016\/j.jpba.2019.113076.","DOI":"10.1016\/j.jpba.2019.113076"},{"key":"10.1016\/j.jchromb.2023.123801_b0125","doi-asserted-by":"crossref","unstructured":"S. Capiau, H. Veenhof, R.A. Koster, Y. Bergqvist, M. Boettcher, O. Halmingh, B.G. Keevil, B.C. Koch, R. Linden, C. Pistos, L.M. Stolk, D.J. Touw, C.P. Stove, J.-W.C. Alffenaar, Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and Validation of Dried Blood Spot-Based Methods for Therapeutic Drug Monitoring, 2019. www.drug-monitoring.com.","DOI":"10.1097\/FTD.0000000000000643"},{"key":"10.1016\/j.jchromb.2023.123801_b0130","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/jphp.12275","article-title":"Pharmacokinetics of rifampicin in Mexican patients with tuberculosis and healthy volunteers","volume":"66","author":"Medell\u00edn-Garibay","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jchromb.2023.123801_b0135","doi-asserted-by":"crossref","unstructured":"R.P. Dash, V. Veeravalli, J.A. Thomas, C. Rosenfeld, N. Mehta, N.R. Srinivas, Whole blood or plasma: what is the ideal matrix for pharmacokinetic-driven drug candidate selection? Future Med. Chem. 13 (2021) 157\u2013171. http:\/\/doi.org\/10.4155\/fmc-2020-0187.","DOI":"10.4155\/fmc-2020-0187"},{"key":"10.1016\/j.jchromb.2023.123801_b0140","doi-asserted-by":"crossref","unstructured":"E. Kassa, B. Enawgaw, A. Gelaw, B. Gelaw, Effect of anti-tuberculosis drugs on hematological profiles of tuberculosis patients attending at University of Gondar Hospital, Northwest Ethiopia, BMC Hematol. 16 (2016) 1. http:\/\/doi.org\/10.1186\/s12878-015-0037-1.","DOI":"10.1186\/s12878-015-0037-1"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023223002118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023223002118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:12:44Z","timestamp":1761606764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023223002118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":28,"alternative-id":["S1570023223002118"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2023.123801","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Standardization and validation of a novel UPLC-MS\/MS method to quantify first line anti-tuberculosis drugs in plasma and dried blood spots","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2023.123801","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"123801"}}